Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid TumorsJulius Strauss, James L. Gulley, Jeffrey Schlom et al.|Clinical Cancer Research|2018Cited by 415
Drozitumab, a Human Antibody to Death Receptor 5, Has Potent Antitumor Activity against Rhabdomyosarcoma with the Expression of Caspase-8 Predictive of ResponseZhigang Kang, Liang Cao|Clinical Cancer Research|2011Cited by 42